A detailed history of Raymond James Financial Services Advisors, Inc. transactions in Novavax Inc stock. As of the latest transaction made, Raymond James Financial Services Advisors, Inc. holds 10,674 shares of NVAX stock, worth $124,138. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,674
Holding current value
$124,138
% of portfolio
0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 19, 2024

BUY
$3.89 - $20.97 $41,521 - $223,833
10,674 New
10,674 $135,000
Q3 2023

Oct 24, 2023

BUY
$6.81 - $9.74 $71,559 - $102,347
10,508 New
10,508 $76,000
Q4 2022

Feb 08, 2023

SELL
$8.86 - $25.04 $49,456 - $139,773
-5,582 Reduced 10.04%
50,006 $514,000
Q3 2022

Oct 25, 2022

BUY
$18.2 - $76.12 $191,864 - $802,457
10,542 Added 23.4%
55,588 $1.01 Million
Q2 2022

Aug 12, 2022

BUY
$36.28 - $75.29 $556,353 - $1.15 Million
15,335 Added 51.61%
45,046 $2.32 Million
Q1 2022

May 11, 2022

BUY
$69.73 - $142.9 $246,565 - $505,294
3,536 Added 13.51%
29,711 $2.19 Million
Q4 2021

Feb 08, 2022

BUY
$134.56 - $217.97 $1.1 Million - $1.78 Million
8,152 Added 45.23%
26,175 $3.75 Million
Q3 2021

Nov 02, 2021

BUY
$177.8 - $270.58 $66,319 - $100,926
373 Added 2.11%
18,023 $3.74 Million
Q2 2021

Aug 11, 2021

SELL
$121.0 - $257.67 $386,716 - $823,513
-3,196 Reduced 15.33%
17,650 $3.75 Million
Q1 2021

May 14, 2021

SELL
$112.98 - $319.93 $154,782 - $438,304
-1,370 Reduced 6.17%
20,846 $3.78 Million
Q4 2020

Feb 12, 2021

BUY
$78.74 - $139.5 $123,858 - $219,433
1,573 Added 7.62%
22,216 $2.48 Million
Q3 2020

Nov 04, 2020

SELL
$79.44 - $178.51 $191,370 - $430,030
-2,409 Reduced 10.45%
20,643 $2.24 Million
Q2 2020

Jul 17, 2020

BUY
$13.86 - $83.61 $134,636 - $812,187
9,714 Added 72.83%
23,052 $1.92 Million
Q1 2020

Apr 21, 2020

BUY
$3.93 - $16.0 $52,418 - $213,408
13,338 New
13,338 $181,000

Others Institutions Holding NVAX

About NOVAVAX INC


  • Ticker NVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,215,104
  • Market Cap $910M
  • Description
  • Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...
More about NVAX
Track This Portfolio

Track Raymond James Financial Services Advisors, Inc. Portfolio

Follow Raymond James Financial Services Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.